[pubmed] Cancer in Myasthenia Gravis subtypes in relation to immunosuppressive treatment and acetylcholine receptor anti

[RSS-Bot]

Eur J Neurol. 2021 Jan 11. doi: 10.1111/ene.14730. Online ahead of print.

ABSTRACT

BACKGROUND AND PURPOSE: The potentially increased risk of extrathymic cancers in MG remains uncertain. We present the occurrence of extrathymic cancer diagnoses in different MG subgroups.

METHODS: A nationwide Swedish register-based cohort study included patients who had their first MG diagnosis or first prescription of acetylcholine esterase inhibitors between the years 2006 and 2018. Timing and subtypes of cancer diagnosis in relation to MG as well as corticosteroid sparing immunosuppressants (CSIS) were identified from national patient-, cancer- and drug registers.

RESULTS: In the study population of 2812 MG patients, 92 patients had juvenile MG (JMG; 3%), 632 had early onset MG (EOMG; 23%), 1968 had late onset MG (LOMG; 70%) and 120 patients had thymoma associated MG (TAMG; 4%). Extrathymic cancers were observed in 630 (22.4%) patients. Skin cancer and cancer in the male genital organs were most common (N= 138 respectively), followed by cancers in the female genital organs (N=103), digestive organs (N= 90) and breast (N=80). TAMG (29.2%) and LOMG (28.4%) patients had the highest occurrence of extrathymic cancer. Cancer frequency was comparable between AChR antibody seropositive and seronegative patients. Two or more CSIS prescriptions significantly increased the frequency of cancer, especially cancers in the digestive organs (P=0.0026), male genital organs (P=0.0037) and the skin (P

Source: https://pubmed.ncbi.nlm.nih.gov/3342738 ... 0&v=2.14.2